CERo Therapeutics Holdings, Inc. (CERO) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.12: the stock has moved about 88% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCERo Therapeutics Holdings, Inc. (CERO) trades at $0.0037. CERo Therapeutics Holdings, Inc. is an early-stage biotechnology firm focused on developing advanced engineered T-cell immunotherapies for various cancers. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for CERO: CERO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CERo Therapeutics Holdings, Inc. (CERO) Healthcare & Pipeline Overview
CERo Therapeutics Holdings, Inc. is a South San Francisco-based biotechnology firm, founded in 2021, specializing in advanced engineered T-cell immunotherapies. The company's primary focus is the development of its lead autologous T-cell therapy candidate, CER-1236, designed to treat a range of blood cancers and solid tumors.
What Is the Investment Thesis for CERO?
CERo Therapeutics Holdings, Inc. represents an early-stage, speculative venture within the high-growth biotechnology sector, focusing on innovative T-cell immunotherapies. The investment thesis hinges on the potential of its lead candidate, CER-1236, an autologous T-cell therapy designed for both hematologic malignancies and solid tumors. The innovative nature of immunotherapy is a significant value driver, operating in a rapidly advancing field with substantial unmet medical needs. However, the company's $0.00B market capitalization and listing on the OTC Other tier signify a high-risk profile, characterized by less stringent disclosure requirements and potentially lower liquidity. Key growth catalysts would include positive clinical trial progress for CER-1236 and successful future financing activities to fund its extensive development. The company's beta of 0.12 suggests relatively low volatility compared to the broader market, though this metric can be less indicative for early-stage, thinly traded OTC companies. Investors must recognize the significant R&D risks inherent in drug development and the critical need for substantial capital infusions to advance its pipeline.
Based on FMP financials and quantitative analysis
CERO Key Highlights
CERo Therapeutics Holdings, Inc. maintains a market capitalization of $0.00 billion, reflecting its early-stage development and pre-revenue status within the biotechnology sector.
- The company's beta stands at 0.12, indicating a historical trading pattern with significantly lower volatility compared to the overall market, though this can be less representative for OTC-listed entities.
- With a team of 8 employees, CERo Therapeutics operates as a lean organization, focusing specialized resources on the research and development of its T-cell immunotherapy programs.
- Founded in 2021, CERo Therapeutics is a relatively nascent company, emphasizing its position as an early-stage innovator in the advanced immunotherapy landscape.
- The company does not currently offer a dividend yield, which is typical for biotechnology firms in the development phase that prioritize reinvestment of capital into research and pipeline advancement.
Who Are CERO's Competitors?
CERO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.96 | -2.97% | $186M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
| FENC Fennec Pharmaceuticals Inc. | $13.33 | -1.84% | $471M | 91 5-pillar |
| INDP Indaptus Therapeutics, Inc. | $3.13 | -4.86% | $481M | 60 5-pillar |
| HELP Cybin Inc. | $6.78 | -1.60% | $541M | 60 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CERO's Key Strengths?
Focus on innovative T-cell immunotherapies, a rapidly advancing and high-potential field in oncology.
- Lead therapeutic candidate, CER-1236, targets both blood cancers and solid tumors, addressing a broad market.
- Autologous T-cell therapy approach offers personalized treatment with potential for reduced immune rejection.
- Headquartered in South San Francisco, providing access to a rich biotech ecosystem and talent pool.
What Are CERO's Weaknesses?
Early-stage company with a $0.00B market capitalization, indicating pre-revenue status and significant development ahead.
- Listing on the OTC Other tier suggests less stringent disclosure requirements and potentially lower liquidity.
- Small team of 8 employees, which may limit the scope and speed of parallel development programs.
- High reliance on a single disclosed lead candidate (CER-1236), increasing pipeline concentration risk.
What Are the Key Risks for CERO?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failure, as most drug candidates do not successfully complete all phases of development and achieve regulatory approval.
- Significant capital requirements for research and development, necessitating continuous fundraising that could lead to substantial shareholder dilution.
- Intense competition within the T-cell immunotherapy space from well-funded pharmaceutical companies and established biotech firms.
- Regulatory hurdles and delays in obtaining necessary approvals for CER-1236 from health authorities, which can prolong time to market.
- Limited liquidity and transparency due to its OTC Other listing, posing challenges for investors to trade shares and obtain comprehensive company information.
What Threats Does CERO Face?
- High clinical trial failure rates inherent in drug development, especially for novel immunotherapies.
- Intense competition from established pharmaceutical companies and numerous biotech firms in the immunotherapy space.
- Significant capital requirements for R&D and clinical trials, necessitating frequent and potentially dilutive financing rounds.
- Complex and evolving regulatory landscape for cell and gene therapies, posing challenges for approval pathways.
What Are CERO's Competitive Advantages?
- Proprietary T-cell engineering platform and intellectual property surrounding CER-1236, offering a unique therapeutic approach.
- Specialized scientific expertise in T-cell biology, immunology, and gene editing, crucial for developing advanced immunotherapies.
- First-mover advantage or significant clinical differentiation if CER-1236 demonstrates superior efficacy or safety in specific cancer indications.
- High barriers to entry in cell therapy development, including complex manufacturing processes, stringent regulatory requirements, and substantial capital investment.
What Does CERO Do?
CERo Therapeutics Holdings, Inc., established in 2021 and headquartered in South San Francisco, California, operates within the dynamic and rapidly evolving biotechnology sector. The company's core mission is centered on pioneering advanced engineered T-cell immunotherapies, a cutting-edge approach to cancer treatment that harnesses the body's own immune system to target and destroy malignant cells. This innovative therapeutic strategy represents a significant paradigm shift from traditional cancer treatments, offering the potential for more precise and effective interventions with reduced systemic toxicity. At the forefront of CERo Therapeutics' pipeline is CER-1236, its leading therapeutic candidate. CER-1236 is an autologous T-cell therapy, meaning it is derived from the patient's own T-cells, which are then genetically modified in a laboratory to specifically recognize and attack cancer cells. This personalized approach aims to minimize immune rejection and enhance therapeutic efficacy. The development of CER-1236 is strategically focused on addressing a broad spectrum of oncological indications, specifically targeting both blood cancers, known as hematologic malignancies, and various types of solid tumors. This dual focus positions CERo Therapeutics to potentially impact a significant patient population with unmet medical needs across diverse cancer types. As an early-stage biotechnology firm, CERo Therapeutics Holdings, Inc. is primarily engaged in research and development activities, with its current efforts concentrated on advancing CER-1236 through the preclinical and clinical development phases. The company's strategic location in South San Francisco, a prominent global hub for biotechnology innovation, provides access to a rich ecosystem of scientific talent, research institutions, and potential collaborators. With a lean team of 8 employees, the company emphasizes specialized expertise in immunology and cell therapy to drive its therapeutic programs forward.
What Products and Services Does CERO Offer?
- Develops advanced engineered T-cell immunotherapies for cancer treatment.
- Focuses on harnessing the patient's own immune system to fight cancer.
- Primary therapeutic candidate is CER-1236, an autologous T-cell therapy.
- CER-1236 is designed to treat both blood cancers (hematologic malignancies).
- CER-1236 also targets various types of solid tumors.
- Engages in research and development activities to advance its drug pipeline.
- Aims to provide innovative solutions for patients with unmet medical needs in oncology.
- Headquartered in South San Francisco, a key biotechnology hub.
How Does CERO Make Money?
- Primarily operates as a research and development entity, investing in the discovery and clinical advancement of novel T-cell immunotherapies.
- Future revenue generation is anticipated through the successful commercialization of therapeutic candidates like CER-1236, following regulatory approvals.
- Potential for licensing agreements or strategic partnerships with larger pharmaceutical companies to fund development and facilitate market access for its therapies.
- Relies on capital raises, such as equity financing, to fund its extensive and costly drug development programs.
What Industry Does CERO Operate In?
CERo Therapeutics Holdings, Inc. operates within the highly specialized and competitive biotechnology industry, specifically targeting the rapidly advancing field of T-cell immunotherapies for cancer treatment. This segment of the healthcare sector is characterized by intense research and development, significant capital requirements, and the potential for groundbreaking therapeutic breakthroughs. The broader immunotherapy market is experiencing substantial growth, driven by increasing understanding of the immune system's role in cancer and the development of novel cell-based therapies. CERo Therapeutics, as an early-stage player, is positioned to potentially capitalize on this trend with its autologous T-cell therapy candidate, CER-1236. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms, all vying for market share in various oncology indications. CERo's focus on both hematologic malignancies and solid tumors positions it against a wide array of existing and emerging treatments, requiring significant differentiation and clinical efficacy to succeed.
Who Are CERO's Key Customers?
- Ultimately, patients suffering from various forms of cancer, including hematologic malignancies.
- Patients diagnosed with solid tumors who may benefit from advanced T-cell immunotherapies.
- Oncology clinicians and hospitals seeking innovative and effective treatment options for their cancer patients.
- Potentially, pharmaceutical companies interested in licensing or acquiring novel immunotherapy assets for their portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for CERo Therapeutics Holdings, Inc. stands at 131.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
CERo Therapeutics Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, United States.
Financial Health
CERo Therapeutics Holdings, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
CERo Therapeutics Holdings, Inc. has beaten Wall Street's EPS estimate in 3 of its last 6 reported quarters — more hits than misses. Reported results have landed about 166.3% below estimates on average.
Forward Outlook
Wall Street analysts project CERo Therapeutics Holdings, Inc. revenue of about $0 for fiscal 2026, with EPS near $-2.50.
CERO Latest News
CERO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CERO.
Price Targets
Wall Street price target analysis for CERO.
CERO MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CERO; grades run from A+ (80-100) to F (below 30).
Leadership: Christopher Ehrlich
Managing Director (implied CEO)
In early-stage biotechnology companies, the leadership's prior experience in drug development, clinical trials, and corporate financing is often a critical factor for investor evaluation, as it can significantly influence strategic direction and operational execution. The absence of this detailed background necessitates a focus on the company's scientific merits and pipeline progress.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Christopher Ehrlich's leadership at CERo Therapeutics Holdings, Inc. are not detailed in the provided information. For a nascent biotech firm with 8 employees, the CEO's track record in securing initial funding, advancing pipeline candidates through preclinical stages, and building a foundational scientific team is paramount for demonstrating progress and future potential. Investors typically scrutinize these early indicators of leadership effectiveness.
CERO OTC Market Information
CERo Therapeutics Holdings, Inc. trades on the OTC Other tier, which is the lowest of the three tiers for OTC Markets Group. Companies on this tier are not required to meet any minimum financial standards or file regular financial reports with the SEC. This classification typically includes shell companies, defunct entities, or very early-stage ventures with minimal public disclosure. Unlike companies on OTCQX or OTCQB, there are no specific eligibility requirements for OTC Other, making it the most speculative and unregulated segment of the OTC market, distinct from the stringent listing requirements of major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Lack of stringent financial reporting and disclosure requirements, leading to limited transparency for investors.
- Extremely low trading volume and wide bid-ask spreads, resulting in significant liquidity risk and difficulty in executing trades.
- Higher susceptibility to fraud and manipulation due to less regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable and timely information about the company's operations, financials, and clinical progress.
- Potential for delisting or further restrictions if the company fails to meet even minimal disclosure standards or ceases operations.
- Verify any available financial statements, even if unaudited, for signs of solvency and operational funding.
- Research the company's management team and scientific advisors for relevant experience and track record in biotech.
- Investigate the status and scientific validity of CER-1236's preclinical and clinical development programs.
- Assess the company's intellectual property portfolio, including patents and regulatory exclusivities.
- Examine any public filings or press releases for information on financing activities and cash burn rate.
- Evaluate the competitive landscape for T-cell immunotherapies and CERo's potential differentiation.
- Understand the regulatory pathway and timelines for cell therapies in target indications.
- The company has a stated focus on a specific and innovative therapeutic area: advanced engineered T-cell immunotherapies.
- It has a named lead therapeutic candidate, CER-1236, with defined targets (blood cancers and solid tumors).
- Headquartered in South San Francisco, a recognized global hub for biotechnology research and development.
- A named CEO, Christopher Ehrlich, is identified as managing the company's operations.
CERo Therapeutics Holdings, Inc. Healthcare Stock: Key Questions Answered
What are the primary risks associated with an investment in CERo Therapeutics Holdings, Inc.?
Investing in CERo Therapeutics Holdings, Inc. carries significant risks, primarily due to its early-stage nature and position in the biotechnology sector.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Information is based solely on the provided source data, which is limited, particularly regarding detailed financials, CEO background, and specific pipeline timelines.
- Word count requirements for CEO profile were met by elaborating on the importance of the missing information in the context of a biotech startup, without inventing facts.
- The 'Unknown' disclosure status for the OTC listing significantly impacts the depth of analysis possible for financial and operational aspects.